Regeneron Pharmaceuticals and Sanofi believe Libtayo (cemiplimab) can be a major player in front-line non-small-cell lung cancer (NSCLC), but, while the partners now look set to secure a seat at the table thanks to a positive Phase III readout, there remains plenty of heavy lifting to compete with the market leader in Merck & Co.'s Keytruda (pembrolizumab).
To provide FirstWord readers with rapid feedback on how the treatment paradigm is shifting and where newer entries like Libtayo fit into the picture, we are hosting an expert call with a key opinion leader (KOL) later this week.
Key topics that will be discussed during the call include, among other things… how are immuno-oncology (I/O) drugs currently being used in front-line NSCLC; how impressive was Libtayo's performance in the Phase III monotherapy trial; are you surprised it hit the early stopping criteria by improving overall survival by 32.4%; are there any notable differences between any of the anti-PD-(L)1 drugs in NSCLC; do you expect to use Libtayo in patients with newly diagnosed NSCLC in the near-term; are there any levers Regeneron/Sanofi could pull to convince oncologists to reach for their drug; how soon do you think the current standard of care in NSCLC will shift; and if/when new I/O combinations arrive, is Merck likely to maintain a dominant position given physician familiarity and comfort with Keytruda?
Ask the expert!
Furthermore, we invite FirstWord Pharma readers to submit their own questions for consideration. Please click here to do so. We can't guarantee that all questions submitted will be asked due to time constraints, but we will do our utmost to cover the important issues relating to the use of Libtayo and other I/O drugs for treating NSCLC.
We endeavour to provide feedback from KOLs as quickly as possible. Interview content will be published for FirstWord Pharma PLUS subscribers to read. To be notified when the interview content is available please click here.
As always, FirstWord would very much like to receive your feedback and suggestions.
To read more KOL Views articles, click here.